1. Home
  2. RMBS vs EXEL Comparison

RMBS vs EXEL Comparison

Compare RMBS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rambus Inc.

RMBS

Rambus Inc.

HOLD

Current Price

$134.05

Market Cap

9.7B

Sector

Technology

ML Signal

HOLD

Logo Exelixis Inc.

EXEL

Exelixis Inc.

HOLD

Current Price

$49.56

Market Cap

11.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMBS
EXEL
Founded
1990
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
11.4B
IPO Year
1997
2000

Fundamental Metrics

Financial Performance
Metric
RMBS
EXEL
Price
$134.05
$49.56
Analyst Decision
Buy
Buy
Analyst Count
7
21
Target Price
$137.00
$46.50
AVG Volume (30 Days)
2.4M
2.6M
Earning Date
04-27-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
27.88
57.95
EPS
0.55
0.79
Revenue
$707,630,000.00
$452,477,000.00
Revenue This Year
$16.01
$13.61
Revenue Next Year
$16.23
$13.13
P/E Ratio
$234.94
$60.63
Revenue Growth
27.13
N/A
52 Week Low
$52.18
$33.76
52 Week High
$161.80
$48.92

Technical Indicators

Market Signals
Indicator
RMBS
EXEL
Relative Strength Index (RSI) 59.86 64.99
Support Level $90.31 $40.17
Resistance Level $161.80 N/A
Average True Range (ATR) 9.22 1.64
MACD -0.26 0.36
Stochastic Oscillator 51.57 86.81

Price Performance

Historical Comparison
RMBS
EXEL

About RMBS Rambus Inc.

Rambus Inc is a semiconductor company providing chips and silicon IP for data-intensive computing systems, focusing on data center and artificial intelligence (AI) infrastructure. The company is at the forefront of enabling the next era of AI-driven computing, addressing challenges of signal and power integrity at increasingly extreme data rates across the data center, edge, and client markets. It offers high-performance memory subsystems, with a balanced and diverse portfolio of products, IP, and patents that maximize performance and security in computationally intensive systems. The company operates in South Korea, Singapore, the United States, and other countries, with the majority of its revenue coming from South Korea.

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: